免疫调节剂在多发性骨髓瘤中的作用机制。
Mechanism of action of immunomodulatory agents in multiple myeloma.
机构信息
VA Boston Healthcare System, Boston, MA, USA.
出版信息
Med Oncol. 2010 Jun;27 Suppl 1(Suppl 1):S7-13. doi: 10.1007/s12032-010-9527-y. Epub 2010 Apr 20.
Abstract
Immunomodulatory agents (IMiD's) have become an important drug category in the treatment of multiple myeloma. The agents have a complex mechanism of action that influence the microenvironment in the bone marrow. The microenvironment is an essential promotor of disease progression and therefore important in targeting the disease. The article reviews mechanism of action and essential pathways of IMiD's that are important in disease treatment.
摘要
免疫调节剂（IMiD's）已成为多发性骨髓瘤治疗中的一个重要药物类别。这些药物具有影响骨髓微环境的复杂作用机制。微环境是疾病进展的重要促进因素，因此在靶向治疗疾病方面非常重要。本文综述了在疾病治疗中重要的 IMiD's 的作用机制和关键途径。
相似文献
1
Mechanism of action of immunomodulatory agents in multiple myeloma.
Med Oncol. 2010 Jun;27 Suppl 1(Suppl 1):S7-13. doi: 10.1007/s12032-010-9527-y. Epub 2010 Apr 20.
2
Novel agents in CNS myeloma treatment.
Cent Nerv Syst Agents Med Chem. 2014;14(1):23-7. doi: 10.2174/1871524914999140818111514.
3
[Pomalidomide for multiple myeloma].
Bull Cancer. 2017 Sep;104(9):707-713. doi: 10.1016/j.bulcan.2017.04.005. Epub 2017 Jun 2.
4
Thalidomide and lenalidomide in multiple myeloma.
Best Pract Res Clin Haematol. 2006;19(4):769-80. doi: 10.1016/j.beha.2006.06.006.
5
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. doi: 10.1053/j.seminhematol.2005.10.001.
6
Lenalidomide in multiple myeloma: Current status and future potential.
Am J Hematol. 2012 Dec;87(12):1089-95. doi: 10.1002/ajh.23234. Epub 2012 May 28.
7
Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
Br J Cancer. 2005 Sep 19;93(6):613-9. doi: 10.1038/sj.bjc.6602774.
8
Lenalidomide in the treatment of multiple myeloma: a review.
J Clin Pharm Ther. 2008 Jun;33(3):219-26. doi: 10.1111/j.1365-2710.2008.00920.x.
9
Lenalidomide mode of action: linking bench and clinical findings.
Blood Rev. 2010 Nov;24 Suppl 1:S13-9. doi: 10.1016/S0268-960X(10)70004-7.
10
Pomalidomide for the management of refractory multiple myeloma.
Am J Health Syst Pharm. 2014 Sep 1;71(17):1443-8. doi: 10.2146/ajhp130752.
引用本文的文献
1
New immunomodulatory anticancer quinazolinone-based thalidomide analogs: design, synthesis and biological evaluation.
Future Med Chem. 2024;16(23):2523-2533. doi: 10.1080/17568919.2024.2419361. Epub 2024 Nov 12.
2
Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms.
J Mol Cell Cardiol. 2024 Sep;194:118-132. doi: 10.1016/j.yjmcc.2024.06.005. Epub 2024 Jun 17.
3
Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs.
Int J Mol Sci. 2023 Aug 4;24(15):12416. doi: 10.3390/ijms241512416.
4
Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview.
Metabolites. 2023 Apr 11;13(4):543. doi: 10.3390/metabo13040543.
5
Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents.
RSC Adv. 2022 Nov 22;12(52):33525-33539. doi: 10.1039/d2ra06188k.
6
Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.
Clin Case Rep. 2022 Sep 19;10(9):e6199. doi: 10.1002/ccr3.6199. eCollection 2022 Sep.
7
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.
Cancers (Basel). 2021 Sep 24;13(19):4787. doi: 10.3390/cancers13194787.
8
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Drugs. 2017 Sep;77(13):1473-1480. doi: 10.1007/s40265-017-0795-0.
9
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.
Onco Targets Ther. 2017 Jan 6;10:217-226. doi: 10.2147/OTT.S112423. eCollection 2017.
10
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Onco Targets Ther. 2016 Aug 5;9:4843-58. doi: 10.2147/OTT.S110189. eCollection 2016.
本文引用的文献
1
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Leukemia. 2009 Dec;23(12):2222-32. doi: 10.1038/leu.2009.179. Epub 2009 Sep 10.
2
Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.
J Bone Miner Metab. 2009;27(1):16-23. doi: 10.1007/s00774-008-0012-z. Epub 2008 Dec 5.
3
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
Ther Clin Risk Manag. 2008 Feb;4(1):129-36. doi: 10.2147/tcrm.s1445.
4
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Leukemia. 2008 Oct;22(10):1925-32. doi: 10.1038/leu.2008.174. Epub 2008 Jul 3.
5
Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
Leuk Lymphoma. 2008 Jul;49(7):1238-45. doi: 10.1080/10428190802005191.
6
Preclinical studies of novel targeted therapies.
Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix. doi: 10.1016/j.hoc.2007.08.013.
7
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
J Clin Oncol. 2007 Oct 1;25(28):4459-65. doi: 10.1200/JCO.2007.12.3463. Epub 2007 Sep 4.
8
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
Leukemia. 2007 Sep;21(9):1875-84. doi: 10.1038/sj.leu.2404843. Epub 2007 Jul 5.
9
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
J Cell Biochem. 2007 Jul 1;101(4):950-68. doi: 10.1002/jcb.21213.
10
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
Br J Haematol. 2007 May;137(3):268-9. doi: 10.1111/j.1365-2141.2007.06538.x.
Zotero 插件